Is there a role for adjuvant docetaxel in patients with high-risk localized prostate cancer who elect for prostatectomy?

Currently, there is no data to support the use of adjuvant docetaxel following radical prostatectomy. Given that these are two entirely different treatments in different patient populations, there is no rationale for extrapolating the results from RTOG0521 to a post-surgical (even if high-risk) popu...